Venom-based peptide therapy: insights into anti-cancer mechanism.
Ontology highlight
ABSTRACT: The 5-year relative survival rate of all types of cancer has increased significantly over the past three decades partly due to the targeted therapy. However, still there are many targeted therapy drugs could play a role only in a portion of cancer patients with specific molecular alternation. It is necessary to continue to develop new biological agents which could be used alone and/or in combination with current FDA approved drugs to treat complex cancer diseases. Venom-based drugs have been used for hundreds of years in human history. Nevertheless, the venom-origin of the anti-cancer drug do rarely appear in the pharmaceutical market; and this is due to the fact that the mechanism of action for a large number of the venom drug such as venom-based peptide is not clearly understood. In this
SUBMITTER: Ma R
PROVIDER: S-EPMC5725072 | biostudies-literature | 2017 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA